ライフサイエンスコーパス: polycystic ovary

1 (anovulation with either hyperandrogenism or polycystic ovaries).

2 However, little is known about the cause of polycystic ovaries.

3 PR-4 females studied did not ovulate and had polycystic ovaries.

4 49 (21%) of the women had polycystic ovaries.

5 oligo-/anovulation, hyper-androgenism and/or polycystic ovaries.

6 y androgen excess, ovulatory dysfunction and polycystic ovaries(1), and is often accompanied by insul

7 es and regular cycles and from 32 women with polycystic ovaries, 16 of whom had regular, ovulatory cy

8 idence of vascular dysfunction in women with polycystic ovaries and are compatible with the hypothesi

9 Polycystic ovaries and hyperandrogenemia are present in

10 eproductive function in women with epilepsy (polycystic ovaries and hyperandrogenemia), this was not

11 We related the prevalence of polycystic ovaries and the plasma concentrations of gona

12 The PCOS rats exhibited irregular estrus, polycystic ovaries, and glucose intolerance.

13 ic ovarian syndrome, asymptomatic women with polycystic ovaries, and healthy controls.

14 Polycystic ovaries are a common disorder associated with

15 women with high ZAG had fewer MetS, IGT and polycystic ovaries as compared with the low ZAG PCOS wom

16 rinology clinics, 20 asymptomatic women with polycystic ovaries attending the family planning clinic,

17 owing 60 subjects: 20 symptomatic women with polycystic ovaries attending the reproductive endocrinol

18 ased density of small preantral follicles in polycystic ovaries could result from increased populatio

19 isease, ovarian primordial follicle loss and polycystic ovary disease were increased in F1 generation

20 emales, ovarian primordial follicle loss and polycystic ovary disease were increased in F3 generation

21 Thin women with polycystic ovaries have altered hypothalamic control of

22 Obese, hirsute women with polycystic ovaries have higher than normal ovarian secre

23 of female infertility and is associated with polycystic ovaries, hirsutism, obesity, and insulin resi

24 tages, was six-fold greater in biopsies from polycystic ovaries in anovulatory women than in normal o

25 ausible explanation for the pathogenesis of "polycystic" ovaries in hyperandrogenism.

26 nosed after irregular menses, hirsutism, and polycystic ovaries, is concerned about weight gain despi

27 nt was observed for heart failure (0.40) and polycystic ovaries or ovarian cysts (0.27).

28 elopment of dysfunctional ovulation, classic polycystic ovaries, reduced large antral follicle health

29 nd is elevated in women with androgen excess polycystic ovary syndrome (AE-PCOS).

30 onfidence interval (95% CI): 1.22-1.53)) and polycystic ovary syndrome (OR = 1.51 (95% CI: 1.33-1.72)

31 eptibility loci that are associated with the polycystic ovary syndrome (PCOS) affection status by scr

32 Polycystic ovary syndrome (PCOS) affects 5% of reproduct

33 Correlates of diagnosed and probable polycystic ovary syndrome (PCOS) among parous women were

34 tatic model assessment [HOMA]) in women with polycystic ovary syndrome (PCOS) and chronic periodontit

35 y and densitometry features in patients with polycystic ovary syndrome (PCOS) and compare them with h

36 terleukin-6 (IL-6) in non-obese females with polycystic ovary syndrome (PCOS) and either clinically h

37 he understanding of the relationship between polycystic ovary syndrome (PCOS) and endometrial cancer

38 red in common reproductive disorders such as polycystic ovary syndrome (PCOS) and hypothalamic amenor

39 tor of MMP-1 (TIMP)-1 ratio in patients with polycystic ovary syndrome (PCOS) and systemically health

40 Pregnant women with polycystic ovary syndrome (PCOS) are often overweight or

41 Early age at menarche (early AAM) and polycystic ovary syndrome (PCOS) are reproductive and me

42 teristics differed in women with and without polycystic ovary syndrome (PCOS) between a Caucasian and

43 As a heterogeneous reproductive disorder, polycystic ovary syndrome (PCOS) can be caused by geneti

44 Women with polycystic ovary syndrome (PCOS) commonly suffer from mi

45 Women with polycystic ovary syndrome (PCOS) commonly suffer from mi

46 EPS) are altered in myotubes from women with polycystic ovary syndrome (PCOS) compared to healthy con

47 Ms R, a 27-year-old woman with polycystic ovary syndrome (PCOS) diagnosed after irregul

48 Women with polycystic ovary syndrome (PCOS) exhibit elevated androg

49 Women with polycystic ovary syndrome (PCOS) frequently experience d

50 Polycystic ovary syndrome (PCOS) has been associated wit

51 ars, it has been clearly documented that the polycystic ovary syndrome (PCOS) has major metabolic seq

52 Women with polycystic ovary syndrome (PCOS) have been shown to be l

53 female first-degree relatives of women with polycystic ovary syndrome (PCOS) have hyperandrogenemia

54 Approximately 70% of women with polycystic ovary syndrome (PCOS) have intrinsic insulin

55 an morphologic measurements for diagnosis of polycystic ovary syndrome (PCOS) in adolescents.

56 or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity i

57 Polycystic ovary syndrome (PCOS) is a common and heterog

58 Polycystic ovary syndrome (PCOS) is a common endocrine d

59 Polycystic ovary syndrome (PCOS) is a common endocrine d

60 Polycystic ovary syndrome (PCOS) is a common endocrine d

61 Polycystic ovary syndrome (PCOS) is a common problem amo

62 Polycystic ovary syndrome (PCOS) is a common, complex ge

63 Polycystic ovary syndrome (PCOS) is a common, highly her

64 Polycystic ovary syndrome (PCOS) is a complex hormonal d

65 Polycystic ovary syndrome (PCOS) is a complex syndrome w

66 Polycystic ovary syndrome (PCOS) is a heterogeneous cond

67 Polycystic ovary syndrome (PCOS) is a heterogenous disor

68 Polycystic ovary syndrome (PCOS) is a hypothalamic-pitui

69 Polycystic ovary syndrome (PCOS) is a leading cause of a

70 Polycystic ovary syndrome (PCOS) is a major reproductive

71 Polycystic ovary syndrome (PCOS) is a multifactorial dis

72 Polycystic ovary syndrome (PCOS) is a prevalent endocrin

73 Polycystic ovary syndrome (PCOS) is a prevalent endocrin

74 Polycystic ovary syndrome (PCOS) is a prevalent endocrin

75 Despite affecting ~11-13% of women globally, polycystic ovary syndrome (PCOS) is a substantially unde

76 Polycystic ovary syndrome (PCOS) is among the most commo

77 The polycystic ovary syndrome (PCOS) is an extremely common

78 Polycystic ovary syndrome (PCOS) is associated with card

79 Polycystic ovary syndrome (PCOS) is associated with insu

80 Polycystic ovary syndrome (PCOS) is associated with symp

81 Polycystic ovary syndrome (PCOS) is associated with the

82 Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingl

83 Polycystic ovary syndrome (PCOS) is characterised by a h

84 Polycystic ovary syndrome (PCOS) is characterized by and

85 Polycystic ovary syndrome (PCOS) is common in women of r

86 Polycystic ovary syndrome (PCOS) is frequently associate

87 nostic criteria in women suspected of having polycystic ovary syndrome (PCOS) is incomplete.

88 Polycystic ovary syndrome (PCOS) is the most common caus

89 Polycystic ovary syndrome (PCOS) is the most common endo

90 Polycystic ovary syndrome (PCOS) is the most common endo

91 Polycystic ovary syndrome (PCOS) is the most common horm

92 Polycystic ovary syndrome (PCOS) is the most common repr

93 ly, some studies have revealed the effect of polycystic ovary syndrome (PCOS) on gingival inflammatio

94 Polycystic ovary syndrome (PCOS) recently has been ident

95 Insulin resistance in polycystic ovary syndrome (PCOS) results from a postbind

96 women in their reproductive age suffer from polycystic ovary syndrome (PCOS) that, alongside subfert

97 ations in B cell numbers are associated with polycystic ovary syndrome (PCOS) through unknown mechani

98 arous women with diagnosed, probable, and no polycystic ovary syndrome (PCOS) throughout 15-year foll

99 The prevalence of polycystic ovary syndrome (PCOS) varies across the globe

100 hyperandrogenic insulin-resistant women with polycystic ovary syndrome (PCOS) who are at increased ri

101 Polycystic ovary syndrome (PCOS) women have a hypercoagu

102 d androgen excess with insulin resistance in polycystic ovary syndrome (PCOS) women.

103 Using an ovine model of polycystic ovary syndrome (PCOS), (pregnant ewes injecte

104 Maternal polycystic ovary syndrome (PCOS), a common metabolic dis

105 This would suggest that maternal polycystic ovary syndrome (PCOS), a condition associated

106 ent study, we evaluate a group of women with polycystic ovary syndrome (PCOS), a condition characteri

107 n to this model because it is usually due to polycystic ovary syndrome (PCOS), a condition in which i

108 nd stroma are also prominent features of the polycystic ovary syndrome (PCOS), a leading cause of inf

109 These include polycystic ovary syndrome (PCOS), abnormal uterine bleed

110 orioretinopathy (CSCR) among transmasculine, polycystic ovary syndrome (PCOS), and androgen-exposed p

111 Endothelin-1 is elevated in women with polycystic ovary syndrome (PCOS), and may play a role in

112 alleles are associated with type 2 diabetes, polycystic ovary syndrome (PCOS), and size at birth.

113 g bacterial vaginosis, gestational diabetes, polycystic ovary syndrome (PCOS), anxiety, depression, a

114 Dyslipidemia is a feature of polycystic ovary syndrome (PCOS), but its pathogenesis r

115 Girls with T2D are at risk of developing polycystic ovary syndrome (PCOS), but the prevalence of

116 Polycystic ovary syndrome (PCOS), characterized by incre

117 Polycystic ovary syndrome (PCOS), characterized by irreg

118 ment parameters across various phenotypes of polycystic ovary syndrome (PCOS), considering body mass

119 ty, and hirsutism, common characteristics of polycystic ovary syndrome (PCOS), improve with even mode

120 iome and chronic metabolic disease including polycystic ovary syndrome (PCOS), is well documented, ho

121 similar to those displayed in patients with polycystic ovary syndrome (PCOS), such as follicular gro

122 oxidative stress, in the pathophysiology of polycystic ovary syndrome (PCOS), the most common endocr

123 upport faster and more accurate diagnosis of polycystic ovary syndrome (PCOS), with a focus on both p

124 resents a significant concern for women with polycystic ovary syndrome (PCOS), with deleterious psych

125 rexposure associated with conditions such as polycystic ovary syndrome (PCOS).

126 thesis and/or metabolism in the aetiology of polycystic ovary syndrome (PCOS).

127 neuropathy, ketoacidosis, hypothyroidism and polycystic ovary syndrome (PCOS).

128 inical atherosclerotic markers in women with polycystic ovary syndrome (PCOS).

129 nt for preventing and treating patients with polycystic ovary syndrome (PCOS).

130 risk of endometrial cancer among women with polycystic ovary syndrome (PCOS).

131 cose homeostasis and hormone levels in women polycystic ovary syndrome (PCOS).

132 ciated with insulin resistance in women with polycystic ovary syndrome (PCOS).

133 levels correlate with increased severity of polycystic ovary syndrome (PCOS).

134 yperandrogenism are the cardinal features of polycystic ovary syndrome (PCOS).

135 s increasing evidence of their importance in polycystic ovary syndrome (PCOS).

136 fertility and thus serve as a model of human polycystic ovary syndrome (PCOS).

137 has metabolic advantages in the treatment of polycystic ovary syndrome (PCOS).

138 to the concentrations that can occur during polycystic ovary syndrome (PCOS).

139 An association between polycystic ovary syndrome (PCOS)and endometrial carcinom

140 of healthy women (n = 9), and in women with polycystic ovary syndrome (PCOS; n = 6) or hypothalamic

141 d androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS; refs. 1,2).

142 ppearing more frequently in type 2 diabetic, polycystic ovary syndrome and CHD cases.

143 Naylor's valuable critique of our study "Polycystic Ovary Syndrome and Endometrial Cancer Risk: R

144 2-1.16; P = 0.007); and genetic liability to polycystic ovary syndrome and endometrioid carcinoma (OR

145 ences in vaginal microbiota between cases of polycystic ovary syndrome and healthy controls.

146 disrupted in pathological conditions such as polycystic ovary syndrome and hypothalamic amenorrhea.

147 In patients with polycystic ovary syndrome and insulin resistance, piogli

148 pecially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good e

149 Obese women with the polycystic ovary syndrome are relatively unresponsive to

150 ed, in part, by PCOS Challenge: The National Polycystic Ovary Syndrome Association and by the Foundat

151 ene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretio

152 In 18 overweight women with IR and polycystic ovary syndrome compared with 12 lean control

153 bout limitations of the test, which included polycystic ovary syndrome falsely inflating AMH levels (

154 s for the analysis of a previously described polycystic ovary syndrome gene expression dataset.

155 MI 33 kg/m(2)), insulin-resistant women with polycystic ovary syndrome had aberrant skeletal muscle m

156 The two common forms of polycystic ovary syndrome have different origins in intr

157 Women with the polycystic ovary syndrome have insulin resistance and hy

158 of underlying androgen excess, particularly polycystic ovary syndrome in women.

159 The polycystic ovary syndrome is a common cause of infertili

160 Polycystic ovary syndrome is characterized by an excess

161 Polycystic ovary syndrome is estimated to affect 5-10% o

162 nce thought to affect primarily adult women, polycystic ovary syndrome is frequently diagnosed during

163 Polycystic ovary syndrome is one of the commonest and co

164 Polycystic ovary syndrome is the most common cause of an

165 the University of California, San Francisco, Polycystic Ovary Syndrome Multidisciplinary Clinic over

166 ndomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate

167 nificant benefit when including metformin in polycystic ovary syndrome treatment regimens.

168 evels, that they hypothesized could point to polycystic ovary syndrome underpinning these association

169 s described in the literature and found that polycystic ovary syndrome was associated with increased

170 The polycystic ovary syndrome was defined according to modif

171 ed controlled trial, 60 infertile women with polycystic ovary syndrome were randomly selected and ass

172 proate, is associated with the occurrence of polycystic ovary syndrome when used in young adulthood o

173 ons, linking dementia with bone development, polycystic ovary syndrome with cardiovascular developmen

174 Polycystic ovary syndrome's (PCOS) main feature is hyper

175 une disorders (type 2 diabetes, obesity, and polycystic ovary syndrome).

176 Polycystic ovary syndrome, a fertility disorder affectin

177 eving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a

178 veral phenotypes, including type 1 diabetes, polycystic ovary syndrome, and birth weight.

179 g obesity, type 2 diabetes, hepatitis C, and polycystic ovary syndrome, and is a primary feature of m

180 a) improves ovulatory function in women with polycystic ovary syndrome, and specific dietary fatty ac

181 ecological conditions-such as endometriosis, polycystic ovary syndrome, and uterine fibroids-have rem

182 drenal hyperplasia, premature adrenarche and polycystic ovary syndrome, as well as in androgen-depend

183 line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, inc

184 In obese women with the polycystic ovary syndrome, decreasing serum insulin conc

185 of start of follow-up, parity, diagnosis of polycystic ovary syndrome, diabetes, chronic hypertensio

186 ental disorders, endometriosis, menorrhagia, polycystic ovary syndrome, dysmenorrhea, leiomyoma, and

187 diagnosis, disease duration, treatment, and polycystic ovary syndrome, endometriosis, bilateral ooph

188 56), after adjustment for education, parity, polycystic ovary syndrome, energy intake, and physical a

189 ease, hypertension, stroke, type 2 diabetes, polycystic ovary syndrome, heart failure, atrial fibrill

190 Early and late menarche, polycystic ovary syndrome, infertility, adverse pregnanc

191 an overview of our current understanding of polycystic ovary syndrome, its epidemiology and natural

192 genes associated with spontaneous abortion, polycystic ovary syndrome, myocardial infarction and mel

193 ively due to its associations with diabetes, polycystic ovary syndrome, obesity and birth size.

194 sed overwhelmingly on affective disorders in polycystic ovary syndrome, overlooking a substantial por

195 eted educational qualification, nulliparity, polycystic ovary syndrome, physical activity, and body m

196 ideline for the Assessment and Management of Polycystic Ovary Syndrome, requiring two out of three cr

197 rched PubMed using a string of variations of polycystic ovary syndrome, therapy/treatment, and adoles

198 s the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory f

199 netic liability to 3 factors (endometriosis, polycystic ovary syndrome, type 2 diabetes) scaled to re

200 sex hormone-dependent cancers and diseases (polycystic ovary syndrome, uterine fibroids, endometrios

201 enetically correlated with endometriosis and polycystic ovary syndrome, we find limited genetic overl

202 ulin resistance is observed in patients with polycystic ovary syndrome, we hypothesized that TAC or S

203 enital adrenal hyperplasia often develop the polycystic ovary syndrome.

204 narche and hyperandrogenic disorders such as polycystic ovary syndrome.

205 serum androgen concentrations in women with polycystic ovary syndrome.

206 associated with infertile conditions such as polycystic ovary syndrome.

207 ix to eight weeks in 44 obese women with the polycystic ovary syndrome.

208 ostic decisions and treating infertility and polycystic ovary syndrome.

209 daily for 35 days in 61 obese women with the polycystic ovary syndrome.

210 genaemia which is a common characteristic of polycystic ovary syndrome.

211 ur to eight weeks in 24 obese women with the polycystic ovary syndrome.

212 0c17 alpha activity are both features of the polycystic ovary syndrome.

213 py, infertility treatment, endometriosis, or polycystic ovary syndrome.

214 mmon health conditions, such as diabetes and polycystic ovary syndrome.

215 iagnoses; 70% of women with anovulation have polycystic ovary syndrome.

216 ess disorder, insomnia, age at menarche, and polycystic ovary syndrome.

217 a gut microbiota-derived metabolite induces polycystic ovary syndrome.

218 troke, nonalcoholic fatty liver disease, and polycystic ovary syndrome.

219 and quality of life of infertile women with polycystic ovary syndrome.

220 ulation rates among infertile women with the polycystic ovary syndrome.

221 seen in diseases of excess androgens such as polycystic ovary syndrome.

222 lays a key role in the early pathogenesis of polycystic ovary syndrome.

223 ND1A) previously shown to be associated with polycystic ovary syndrome.

224 of adolescents are presenting with signs of polycystic ovary syndrome.

225 y in symptomatic and asymptomatic women with polycystic ovaries than in the controls (10.7, 14.1, and

226 In both ovulatory and anovulatory women with polycystic ovaries, we noted a significant increase in t

227 n disease (primary ovarian insufficiency and polycystic ovaries) were increased in the F3 generation